Ishika Govil

Ishika Govil

Auto-generated profile, based on publicly available information

Ishika Govil

Department of Chemical Engineering, MIT, Cambridge, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2025 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
JSJessica C. Stark
Jessica C. Stark
MGMelissa A. Gray
Melissa A. Gray
IIItziar Ibarlucea-Benitez
Itziar Ibarlucea-Benitez
MLMarta Lustig
Marta Lustig
ABAnnalise Bond
Annalise Bond
CBCarolyn Bertozzi
Carolyn Bertozzi
Despite the curative potential of checkpoint blockade immunotherapy, many patients remain unresponsive to existing treatments. Glyco-immune checkpoints, which involve interactions of cell-surface glycans with lectin, or glycan-binding, immunoreceptors, have emerged as prominent mechanisms of immune evasion and therapeutic resistance in cancer. Here, we describe antibody-lectin chimeras (AbLecs), a modular system for glyco-immune checkpoint blockade. AbLecs are bispecific antibody-like molecules comprising a cell-targeting antibody domain and a lectin ‘decoy receptor’ domain that directly binds glycans and blocks their ability to engage inhibitory lectin receptors. AbLecs potentiate cancer cell destruction by primary human immune cells in vitro and reduce tumour burden in a humanized, immunocompetent mouse model, outperforming most existing therapies and combinations tested. By targeting a distinct axis of immunological regulation, AbLecs synergize with blockade of established immune checkpoints. AbLecs can be readily designed to target numerous tumours and immune cell subsets as well as glyco-immune checkpoints, thus representing a potential modality for cancer immunotherapy.

2 May 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
RDRoman M. Dickey
Roman M. Dickey
MJMichaela A. Jones
Michaela A. Jones
NBNeil D. Butler
Neil D. Butler
IGIshika Govil
Ishika Govil
AKAditya M. Kunjapur
Aditya M. Kunjapur
Deconstruction of polyethylene terephthalate (PET) plastic waste generates opportunities for valorization to alternative products. We recently designed an enzymatic cascade that could produce terephthalaldehyde (TPAL) from terephthalic acid. Here, we showed that the addition of TPAL to growing cultures of Escherichia coli wild-type strain MG1655 and an engineered strain for reduced aromatic a ldehyde re ction (RARE) strain resulted in substantial reduction. We then investigated if we could mitigate this reduction using multiplex automatable genome engineering (MAGE) to create an E. coli strain with 10 additional knockouts in RARE. Encouragingly, we found this newly engineered strain enabled a 2.5-fold higher retention of TPAL over RARE after 24h. We applied this new strain for the production of para -xylylenediamine (pXYL) and observed a 6.8-fold increase in pXYL titer compared to RARE. Overall, our study demonstrates the potential of TPAL as a versatile intermediate in microbial biosynthesis of chemicals that derived from waste PET.